Roche Says Phase II Trial Supports Twin Treatment for Kidney Cancer Roche Says Phase II Trial Supports Twin Treatment for Kidney Cancer

Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq (atezolizumab) and its cancer drug Avastin (bevacizumab) had shown encouraging results in a Phase II trial in treating a type of kidney cancer.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news